Ultragenyx preps for pivotal trial in Angelman syndrome, an area where others fell short: #AAN24
Ultragenyx is inching closer to a Phase 3 study for its Angelman syndrome program, known as GTX-102.
In a Phase 1/2 update Monday morning ahead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
